Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab on Saphenous Vein Graft Patency Following CABG
NCT03900026Phase 4Completed
- Sponsor
- Unity Health Toronto
- Start
- May 2019
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 4, randomised, double-blind trial in vein graft occlusion and atherosclerosis comparing Evolocumab Treatment with Placebo Treatment (2 arms). Primary endpoint: Saphenous vein graft disease rate at 24 months. Started May 2019; status: completed.
02
Drugs
evolocumab
03
Conditions
vein graft occlusionatherosclerosis
Beyond the preview
Go deeper on NCT03900026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900026.